Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)
Meeting – October 8, 2025 @ 4:00pm
at the
Oklahoma Health Care Authority (OHCA)
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

NOTE: ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Haymore, Chairman:

1. **Call to Order**

A. Roll Call – Dr. Wilcox

DUR Board Members:

Dr. Cassidy Blaiss –	participating in person
Mr. Kenneth Foster –	participating in person
Dr. Bret Haymore –	participating in person
Dr. Bethany Holderread –	participating in person
Dr. Matt John –	participating in person
Dr. Craig Kupiec –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. Edna Patatanian –	participating in person
Dr. Jennifer Weakley –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:
https://oklahoma.zoom.us/webinar/register/WN_B7-m8jKcQWaA9HEiV7QRQA
After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:
Dial: +1-602-753-0140 or +1-669-219-2599
Webinar ID: 928 6649 0447
Passcode: 80744869

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the Speaker Registration Form. Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Haymore, Chairman:

2. **Public Comment Forum**
   A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Haymore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**
   A. September 10, 2025 DUR Board Meeting Minutes
   B. September 10, 2025 DUR Board Recommendations Memorandum

Non-presentation items reviewed by Dr. DeRemer, Dr. Haymore, Chairman:

4. **Update on Medication Coverage Authorization Unit – See Appendix B**
   A. Pharmacy Help Desk Activity for September 2025
   B. Medication Coverage Activity for September 2025

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

5. **Fall Pipeline Update – See Appendix C**
   A. Introduction
   B. Product Summaries
   C. Pipeline Table

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

6. **Action Item – Vote to Prior Authorize Attruby™ (Acoramidis) and Update the Approval Criteria for the Amyloidosis Medications – See Appendix D**
   A. Market News and Updates
   B. Attruby™ (Acoramidis) Product Summary
   C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

7. **Action Item – Vote to Prior Authorize Alyftrek® (Vanzacaftor/Tezacaftor/Deutivicaftor) and Update the Approval Criteria for the Cystic Fibrosis (CF) Medications – See Appendix E**
   A. Market News and Updates
   B. Alyftrek® (Vanzacaftor/Tezacaftor/Deutivicaftor) Product Summary
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

8. **Action Item – Vote to Prior Authorize Encelto™ (Revakinagene Taroretcel-lwey) – See Appendix F**
   A. Encelto™ (Revakinagene Taroretcel-lwey) Product Summary
   B. College of Pharmacy Recommendations

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

9. **Action Item – Vote to Prior Authorize Fosrenol® (Lanthanum Carbonate) 750mg and 1,000mg Oral Powder Packet and Update the Approval Criteria for the Hyperphosphatemia Medications – See Appendix G**
   A. Cost Comparison: Lanthanum Carbonate Products
   B. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

10. **Action Item – Vote to Prior Authorize Photrexa®/Photrexa® Viscous (Riboflavin 5'-Phosphate) – See Appendix H**
    A. Photrexa®/Photrexa® Viscous (Riboflavin 5'-phosphate) Product Summary
    B. College of Pharmacy Recommendations

Items to be presented by Dr. Sinko, Dr. Haymore, Chairman:

11. **Action Item – Vote to Prior Authorize Datroway® (Datopotamab Deruxtecan-dlnk) and Itovebi™ (Inavolisib) and Update the Approval Criteria for the Breast Cancer Medications – See Appendix I**
    A. Market News and Updates
    B. Product Summaries
    C. Cost Comparison: Trastuzumab Products
    D. College of Pharmacy Recommendations

Non-presentation items reviewed by Dr. Sinko, Dr. Haymore, Chairman:

12. **Annual Review of Myeloproliferative Neoplasm (MPN) Medications – See Appendix J**
    A. Current Prior Authorization Criteria
    B. Utilization of MPN Medications
    C. Prior Authorization of MPN Medications
    D. Market News and Updates
    E. College of Pharmacy Recommendations
    F. Utilization Details of MPN Medications

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

13. **Action Item – Annual Review of *Clostridioides difficile (C. difficile)* Medications – See Appendix K**
    A. Current Prior Authorization Criteria
    B. Utilization of *C. difficile* Medications
    C. Prior Authorization of *C. difficile* Medications
    D. Market News and Updates
    E. College of Pharmacy Recommendations
    F. Utilization Details of *C. difficile* Medications

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

14. **Action Item – Annual Review of Allergen Immunotherapies – See Appendix L**
    A. Current Prior Authorization Criteria
    B. Utilization of Allergen Immunotherapies
    C. Prior Authorization of Allergen Immunotherapies
    D. Market News and Updates
    E. College of Pharmacy Recommendations
    F. Utilization Details of Allergen Immunotherapies

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

15. **Action Item – Annual Review of Cushing's Syndrome Medications – See Appendix M**
    A. Current Prior Authorization Criteria
    B. Utilization of Cushing's Syndrome Medications
    C. Prior Authorization of Cushing's Syndrome Medications
    D. Market News and Updates
    E. College of Pharmacy Recommendations
    F. Utilization Details of Cushing's Syndrome Medications

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

16. **Action Item – Annual Review of Ophthalmic Anti-Inflammatory Products – See Appendix N**
    A. Current Prior Authorization Criteria
    B. Utilization of Ophthalmic Anti-Inflammatory Products
    C. Prior Authorization of Ophthalmic Anti-Inflammatory Products
    D. Market News and Updates
    E. College of Pharmacy Recommendations
    F. Utilization Details of Ophthalmic Anti-Inflammatory Products

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

17. **Action Item – Annual Review of Hyperoxaluria Medications – Appendix O**
    A. Current Prior Authorization Criteria
    B. Utilization of Hyperoxaluria Medications
    C. Prior Authorization of Hyperoxaluria Medications

D. Market News and Updates
E. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

18. Action Item – Annual Review of Anemia Medications – See Appendix P

A. Current Prior Authorization Criteria
B. Utilization of Anemia Medications
C. Prior Authorization of Anemia Medications
D. Market News and Updates
E. College of Pharmacy Recommendations
F. Utilization Details of Anemia Medications

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

19. Annual Review of Targeted Immunomodulator Agents and 30-Day Notice to Prior Authorize Avtozma® (Tocilizumab-anoh), Imuldosa® (Ustekinumab-srlf), Otezla XR™ [Apremilast Extended-Release (ER)], Starjemza™ (Ustekinumab-hmny), Steqeyma® (Ustekinumab-stba), and Yesintek™ (Ustekinumab-kfce) – See Appendix Q

A. Current Prior Authorization Criteria
B. Utilization of Targeted Immunomodulator Agents
C. Prior Authorization of Targeted Immunomodulator Agents
D. Market News and Updates
E. Cost Comparison
F. College of Pharmacy Recommendations
G. Utilization Details of Targeted Immunomodulator Agents

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

20. Annual Review of Hereditary Angioedema (HAE) Medications and 60-Day Notice to Prior Authorize Andembry® (Garadacimab-gxii), Dawnzera™ (Donidalorsen), and Ekterly® (Sebetralstat) and Create a Product Based Prior Authorization (PBPA) Category for the HAE Medications – See Appendix R

A. Current Prior Authorization Criteria
B. Utilization of HAE Medications
C. Prior Authorization of HAE Medications
D. Market News and Updates
E. Product Summaries
F. Cost Comparison: HAE Prophylaxis Products
G. College of Pharmacy Recommendations
H. Utilization Details of HAE Medications

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

21. Annual Review of Anticoagulants and Platelet Aggregation Inhibitors and 30-Day Notice to Prior Authorize Eliquis® (Apixaban) Tablet for Oral

Suspension and Eliquis® Sprinkle (Apixaban) Capsule for Oral Suspension – See Appendix S

A. Current Prior Authorization Criteria
B. Utilization of Anticoagulants and Platelet Aggregation Inhibitors
C. Prior Authorization of Anticoagulants and Platelet Aggregation Inhibitors
D. Market News and Updates
E. College of Pharmacy Recommendations
F. Utilization Details of Anticoagulants and Platelet Aggregation Inhibitors

Non-presentation items reviewed by Dr. DeRemer, Dr. Haymore, Chairman:

22. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix T

Items to be presented by Dr. Adams, Dr. Haymore, Chairman:

23. Future Business* (Upcoming Product and Class Reviews)

A. Amino Acid Disorder Medications
B. Asthma and Chronic Obstructive Pulmonary Disease (COPD) Maintenance Medications
C. Atopic Dermatitis Medications
D. Brinsupri™ (Brensocatib)
E. Butalbital Medications
F. Multiple Myeloma Medications
G. Osteoporosis Medications and Denosumab Products

*Future product and class reviews subject to change.

24. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.

NOTE: Oklahoma Medicaid transitioned from a fee-for-service (FFS) pharmacy benefit to a managed care pharmacy benefit for most members on April 1, 2024. At that time, the majority of SoonerCare members were transitioned to one of the three managed care SoonerSelect plans: Aetna, Humana, or Oklahoma Complete Health. SoonerSelect data has been provided to the College of Pharmacy and has been used in analyses throughout this DUR Board meeting packet. The data included in this DUR Board meeting packet combines FFS and managed care utilization data. The managed care utilization and prior authorization (PA) data reported in this packet is based solely on the data provided by the SoonerSelect plans. SoonerSelect PA data only includes medications billed as pharmacy claims (NDC) and does not include those billed as medical claims (HCPCS), where applicable.